In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach to fight cancers. This approach consists of …

In recent decades, the advent of immune-based therapies, most notably Chimeric antigen
receptor (CAR)-T cell therapy has revolutionized cancer treatment. The promising results of …

Adoptive T cell immunotherapy is a promising treatment strategy for epithelial ovarian
cancer (EOC). However, programmed death ligand‐1 (PD‐L1), highly expressed on EOC …

Adoptive cell therapies engineered to express chimeric antigen receptors (CARs) or
transgenic T cell receptors (TCRs) to recognize and eliminate cancer cells have emerged as …

Chimeric antigen receptor (CAR) T-cell therapy entails the genetic engineering of a patient's
T-cells to express membrane spanning fusion receptors with defined specificities for tumor …

Ovarian cancer (OC) is among the most common gynecologic malignancies with a poor
prognosis and a high mortality rate. Most patients are diagnosed at an advanced stage …

Despite several advances, 5-year survival in patients with head and neck squamous cell
carcinoma (HNSCC) remains unchanged at only 50%. The commonest cause of death is …

The ErbB network is dysregulated in many solid tumors. To exploit this, we have developed
a chimeric Ag receptor (CAR) named T1E28z that targets several pathogenetically relevant …

Expression of the αvβ6 integrin is upregulated in several solid tumors. In contrast,
physiologic expression of this epithelial-specific integrin is restricted to development and …

Immuno‐oncology has been at the forefront of cancer treatment in recent decades. In
particular immune checkpoint and chimeric antigen receptor (CAR)‐T cell therapy have …